Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients
about
Pneumocystis jirovecii Pneumonia in Rheumatoid Arthritis Patients: Risks and Prophylaxis RecommendationsBlocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statementTargeting Low Disease Activity in Elderly-Onset Rheumatoid Arthritis: Current and Future Roles of Biological Disease-Modifying Antirheumatic DrugsTuberculosis vaccines: barriers and prospects on the quest for a transformative toolUse of data from multiple registries in studying biologic discontinuation: challenges and opportunitiesThe risk of tuberculosis disease in rheumatoid arthritis patients on biologics and targeted therapy: A 15-year real world experience in Taiwan.Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted BiologicsHerpes zoster and tofacitinib therapy in patients with rheumatoid arthritis.Tocilizumab induced acquired factor XIII deficiency in patients with rheumatoid arthritis.Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registryTocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions.Radiological features and therapeutic responses of pulmonary nontuberculous mycobacterial disease in rheumatoid arthritis patients receiving biological agents: a retrospective multicenter study in Japan.Pneumocystis jirovecii infection: an emerging threat to patients with rheumatoid arthritis.Tocilizumab in rheumatoid arthritis: efficacy, safety and its place in therapy.Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practiceEfficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study.Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritisTocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan.Incidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis - a systematic evaluation of the literature.Interleukin 6 and rheumatoid arthritisTocilizumab in the treatment of rheumatoid arthritis and beyond.A review of tocilizumab treatment in 122 rheumatoid arthritis patients included in the Tsurumai Biologics Communication Registry (TBCR) Study.Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy.Intravenous tocilizumab: a review of its use in adults with rheumatoid arthritis.The safety of biologic therapies in RA-associated interstitial lung disease.Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae.Adverse reactions to biologic agents and their medical management.Treatment of severe non-infectious uveitis in high-risk conditions (Part 2): systemic infections; management and safety issues.The role of IL-6 in host defence against infections: immunobiology and clinical implications.The Risk of Hypersensitivity Associated with Biologic Use among Medicare Patients with Rheumatoid Arthritis.[Medicinal prophylaxis during intensified immunosuppression in children and adolescents : part 2].Long-term safety and effectiveness of adalimumab for the treatment of Japanese patients with rheumatoid arthritis: 3-year results from a postmarketing surveillance of 552 patients.[Safe use of biological therapies for the treatment of rheumatoid arthritis and spondyloarthritides].Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE.Does tocilizumab contribute to elevation of rheumatoid factor and induction of paradoxical syaloadenitis in rheumatoid arthritis patients?Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis.Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice.Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patients.
P2860
Q26781920-BBB2BB01-836B-40EF-A65D-883CF9D3842CQ27021115-4CF78576-252C-434E-9C16-E67B24C71718Q28073436-9D2DDE7E-73E1-4273-ACA3-EAD238A59216Q28390218-F3532381-462E-4DD4-8E27-ACC6AA38E417Q30678187-6BD2B34A-B5D9-4432-9150-B5EB7D753571Q33751643-4135221E-A904-4856-ADCF-813367622FF8Q33809045-DC83DD73-EC3D-406D-B044-0FF68B15BEA5Q34851473-DFF8AA92-067F-4418-9068-7353AA7E8CBCQ34924736-74723C36-B043-4E40-9AA0-5910461C6ADEQ35258244-13A21FF0-B663-4ECA-B26F-CFF33CFB4803Q35724900-77850262-3F99-443A-8201-AEAD43C0D620Q36230244-336F5CE9-1795-44E5-A904-A22620F16B31Q36434896-695C529C-E097-4A9C-8A0B-ADC6246E8547Q36515498-02B6AD2C-D1FC-467B-98C5-33884B841C85Q36677277-8D5DBC77-D664-4000-8160-99891BD24D2EQ36679764-DCB5413F-ED3B-4DF5-A43E-9CA604BD083AQ36761766-B4727A2F-295C-4569-9751-0DBA6DF54EE5Q36981540-AB209C4D-6779-41D7-A27A-CB128A07A6D9Q37235737-151CE18F-B3A7-4653-80AB-983A56A33C1FQ37358271-4A9FA2F9-2686-4472-B6E8-F857C0A1B88EQ37553940-43E9A2BC-BF03-4D23-9B46-D47CF9726E26Q37682799-F4F4B70F-5C32-4AA3-B352-251EA535A2F3Q38004836-2FF1FD01-3365-410B-B602-2147A75ABC9CQ38116751-AE856827-6A4B-4063-8264-5E943D051A3FQ38164315-56D89C57-99AC-4601-AA46-8100CDD4D080Q38173669-F4986960-3D2A-4A07-8362-8B3F9DC7B1B6Q38176745-DFE2DE5E-B2BC-4767-BB39-739733A58537Q38192553-B21B8F35-FD57-4411-84C9-78A7ED98DE0CQ38238948-1A3C10B9-4ED7-4387-A2DE-17A3692857A1Q38539281-F99CD209-C5E9-4FB6-9ADC-C8BCBCA523C7Q38725223-4D4A2E44-92D9-4DC1-A1CE-3D27E2429542Q39215589-488199AD-FA9C-4176-8945-A80CF08B9B58Q40238572-2D0ED966-21D5-4023-8DC5-A42EADF0E538Q40253228-ACA3F78B-372F-4EA0-805F-9EDE244003B3Q41176187-1DA75704-0263-4A6A-A4A4-EC6FCA48B485Q41928628-DA3E1A03-3365-4FDB-A3BE-067F4579410DQ42254666-3932514E-8A58-4AE4-8EDD-7994E7B87D02Q42578542-C2E6D2E2-2C67-4910-B2EE-F3A2DBC56BD4Q42684613-6C0C2804-10C7-4B52-B299-8EE22B6AB1B0Q45098990-E2E7F8F6-A1C0-4582-A602-FC0A5561B033
P2860
Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Postmarketing surveillance of ...... erim analysis of 3881 patients
@ast
Postmarketing surveillance of ...... erim analysis of 3881 patients
@en
type
label
Postmarketing surveillance of ...... erim analysis of 3881 patients
@ast
Postmarketing surveillance of ...... erim analysis of 3881 patients
@en
prefLabel
Postmarketing surveillance of ...... erim analysis of 3881 patients
@ast
Postmarketing surveillance of ...... erim analysis of 3881 patients
@en
P2093
P2860
P356
P1476
Postmarketing surveillance of ...... erim analysis of 3881 patients
@en
P2093
Hisashi Yamanaka
Junnosuke Ryu
Masayoshi Harigai
Naoki Ishiguro
Shigeko Inokuma
Syuji Takei
Tsutomu Takeuchi
Yoshiya Tanaka
P2860
P304
P356
10.1136/ARD.2011.151092
P407
P50
P577
2011-08-17T00:00:00Z